GSK plc (GSK,GSK.L), a biopharmaceutical company, on Tuesday said it has commenced the third tranche valued at up to 0.3 billion pounds of its previously announced 2 billion pounds share buyback programme, which is scheduled to run through the end of the second quarter of 2026.
The third tranche will run from September 30 through December 19.
The company said the purpose of the programme is to return excess capital to shareholders and reduce its share capital, which is expected to enhance earnings per share.
The first tranche of the programme, up to 0.7 billion pounds, was completed between February 24 and June 3. The second tranche, up to 0.45 billion pounds, ran from June 4 to September 18.
The buybacks will take place on the London Stock Exchange and Cboe Europe order books.
The authority to repurchase shares, up to 413,957,879 ordinary shares, was granted at GSK's 2025 Annual General Meeting.
On Monday, GSK closed trading, 3.14% higher at $41.10 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.